The FDA's fast track program facilitates the development and expedites the review of drugs intended for the treatment of serious or life-threatening diseases and that demonstrate the potential to address unmet medical needs for such conditions. The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition. Once approved, the FDA may not approve any other applications to market the same drug for the same indication, except in very limited circumstances, for seven years. Interferon gamma is biologically distinct from Interferon alpha and Interferon beta, two related proteins that are currently marketed for the treatment of diseases such as hepatitis B infection and multiple sclerosis. InterMune Pharmaceuticals, Inc. develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders.
Injection is intended and relevant for United States residents only.
Countries outside of the United States may have different regulatory requirements and review practices that may require referencing different information. All information on this website is for educational purposes and should not replace discussions with healthcare professionals.